


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula



wherein m represents 1, 2 or 3;

each R^1 independently represents a hydrogen or halogen atom;

one of R^2 and R^3 represents halogen, nitro, amino, hydroxyl, or a group

selected from (i) C_1 - C_6 alkyl optionally substituted by at least one halogen atom,

(ii) C_3 - C_8 cycloalkyl, (iii) C_1 - C_6 alkoxy optionally substituted by at least one halogen atom, and


(iv) C_3 - C_8 cycloalkyloxy, and the other of R^2 and R^3 represents a hydrogen or halogen atom;

n represents 0, 1 or 2; and

R^4 and R^5 each independently represent a hydrogen atom or a C_1 - C_6 alkyl group optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Original) A compound according to claim 1, wherein m is 1.
3. (Currently amended) A compound according to claim 1 ~~or claim 2~~, wherein R³ represents a hydrogen atom.
4. (Currently amended) A compound according to ~~any one of claims 1 to 3~~ claim 1, wherein n is 1.
5. (Original) A compound according to claim 4, which has the following stereochemistry:



6. (Currently amended) A compound according to ~~any one of claims 1 to 5~~ claim 1, wherein R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₆ alkyl group optionally substituted by at least one hydroxyl group.
7. (Original) A compound according to claim 1, wherein
m represents 1;
each R¹ represents a hydrogen atom;

one of R^2 and R^3 represents a halogen atom, and the other of R^2 and R^3 represents a hydrogen atom;

n is 0, 1 or 2; and

R^4 and R^5 each independently represent a hydrogen atom or a group selected from $-CH_3$, $-C_2H_5$, $-CH(CH_3)_2$ and $-(CH_2)_3OH$.

8. (Original) A compound according to claim 1, wherein
 m represents 1;
each R^1 represents a hydrogen atom;
one of R^2 and R^3 represents a halogen atom, and the other of R^2 and R^3 represents a hydrogen atom;

n is 0, 1 or 2; and

one of R^4 and R^5 represents a hydrogen atom or $-CH_3$ and the other of R^4 and R^5 represents a group selected from $-CH_3$, $-C_2H_5$, $-CH(CH_3)_2$ and $-(CH_2)_3OH$.

9. (Original) A compound being selected from any one of:
2-Chloro-5-[(3S)-3-hydroxy-4-(methylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,
2-Chloro-5-[(3S)-3-hydroxy-4-(ethylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,
2-Chloro-5-[(3S)-3-hydroxy-4-(1-methylethylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,
2-Chloro-5-[(3R)-3-hydroxy-4-(methylamino)butyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,
2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,
2-Chloro-5-[(2R)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-
1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2R)-3-(dimethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-
1-ylmethyl)-benzamide,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1S)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)benzamide,

2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)benzamide hydrochloride,

2-Chloro-5-[(1R)-1-hydroxy-2-(methylamino)ethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)benzamide,

2-Chloro-5-[(1R)-2-(ethylamino)-1-hydroxyethyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)benzamide,

2-Chloro-5-[(1R)-1-hydroxy-2-[(3-hydroxypropyl)amino]ethyl]-*N*-
(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2S)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-
ylmethyl)-benzamide,

2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide hydrochloride,

2-Chloro-5-[(2S)-3-(ethylamino)-2-hydroxypropyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,


2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide benzoic acid salt,

2-Chloro-5-[(2R)-2-hydroxy-3-(methylamino)propyl]-*N*-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,

and all pharmaceutically acceptable salts and solvates thereof.


10. (Original) A process for the preparation of a compound according to claim 1, which comprises:

(i) when *n* is 0, reacting a compound of formula



wherein *m*, *R*¹, *R*² and *R*³ are as defined in formula (I), with a compound of formula (III), HNR⁴R⁵, wherein *R*⁴ and *R*⁵ are as defined in formula (I); or


(ii) when *n* is 1, reacting a compound of formula



(IV)

wherein m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or


(iii) when n is 2, reacting a compound of formula



(V)

wherein L^1 is a leaving group and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above; or

(iv) when n is 1, reacting a compound of formula



wherein L^2 is a leaving group and m , R^1 , R^2 and R^3 are as defined in formula (I), with a compound of formula (III) as defined in (i) above;

and optionally after (i), (ii) (iii) or (iv) carrying out one or more of the following:

- converting the compound obtained to a further compound of formula (I)
- forming a pharmaceutically acceptable salt or solvate of the compound.

11. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 9~~ claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

12. (Currently amended) A process for the preparation of a pharmaceutical composition ~~as claimed in claim 11~~ which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in ~~any one of claims 1 to 9~~ claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

13-18. (Cancelled)

19. (Currently amended) A method of treating rheumatoid arthritis or osteoarthritis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 9~~ claim 1.

20. (Currently amended) A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in ~~any one of claims 1 to 9~~ claim 1.

21. (New) The method of claim 20, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.

22. (New) A method of treating atherosclerosis which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in claim 1.